Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erythropoietin in amyotrophic lateral sclerosis
2009-016066-91Phase 3Active
- Sponsor
- Carlo Besta Neurological Institute
- Start
- Nov 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in amyotrophic lateral sclerosis (ALS) comparing Erythropoietin with Placebo (2 arms). Primary endpoints: Survival rate, Tracheotomy or prolonged non-invasive ventilation and 1 more. Started Nov 2009; status: active.
02
Drugs
erythropoietin
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2009-016066-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016066-91.